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Abstract
Background: Reduced uteroplacental perfusion, the initiating event in preeclampsia, is associated with enhanced
endothelin-1 (ET-1) production which feeds the vasoconstriction of uterine artery. Whether the treatments of preeclampsia
were effective on ET-1 induced contraction and could reverse placental ischemia is the question addressed in this study. We
investigated the effect of antihypertensive drugs used in preeclampsia and of ET receptor antagonists on the contractile
response to ET-1 on human uterine arteries.
Methodology/Principal Findings: Experiments were performed, ex vivo, on human uterine artery samples obtained after
hysterectomy. We studied variations in isometric tension of arterial rings in response to the vasoconstrictor ET-1 and
evaluated the effects of various vasodilators and ET-receptor antagonists on this response. Among antihypertensive drugs,
only dihydropyridines were effective in blocking and reversing the ET-1 contractile response. Their efficiency, independent
of the concentration of ET-1, was only partial. Hydralazine, alpha-methyldopa and labetalol had no effect on ET-1 induced
contraction which is mediated by both ETA and ETB receptors in uterine artery. ET receptors antagonists, BQ-123 and BQ-
788, slightly reduced the amplitude of the response to ET-1. Combination of both antagonists was more efficient, but it was
not possible to reverse the maximal ET-1-induced contraction with antagonists used alone or in combination.
Conclusion: Pharmacological drugs currently used in the context of preeclampsia, do not reverse ET-1 induced contraction.
Only dihydropyridines, which partially relax uterine artery previously contracted with ET-1, might offer interesting
perspectives to improve placental perfusion.
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Introduction
Preeclampsia (PE) is a pregnancy-specific vasoconstrictive
disorder, characterized by the development of hypertension and
proteinuria after 20 weeks of gestation in previously normotensive,
non-proteinuric women [1]. Hypertension, which develops during
pregnancy, remits spontaneously after delivery.
PE is associated with abnormal placentation consecutive to
alterations in the vascular remodeling of uteroplacental arteries
mainly due to abnormal invasion of trophoblasts and unconverted
narrow spiral arteries [2]. These processes are the cause of
underperfusion and persistent hypoxia in the placenta [3,4]
leading to an imbalanced production of vasoactive factors [5].
Thus, the placenta is thought to release various mediators into the
maternal circulation, which causes local endothelial dysfunction
and vasoconstriction of uterine arteries [6], and contributes to
systemic blood pressure elevation [7]. Among these substances,
endothelin-1 (ET-1), a potent vasoactive peptide produced by
endothelial cells, appears to be increased [8–10] thereby
promoting vasospasms and impairing uteroplacental blood flow
[11,12]. Elevation of plasma concentrations of ET-1, is involved in
the vasoconstriction of uterine artery associated with the syndrome
[10,13,14] and contributes to systemic hypertension [15]. Blood
pressure and ET-1 concentration rapidly return to normal levels
within 48 h after delivery of the placenta.
Current treatments for PE are aimed at normalizing blood
pressure rather than targeting the pathology itself, but none is
really satisfactory. In most cases, hypertension is reduced only
transiently, allowing a caesarean delivery to be set up before term.
The main treatment recommendations include the use of
antihypertensive drugs such as the calcium (Ca
2+) channel blockers
of the dihydropyridine class (DHP) (nifedipine or nicardipine),
vasodilators (e.g. labetalol or hydralazine), antihypertensive
(methyldopa) and magnesium sulfate [16].
If ET-1 plays a central role in the vasoconstriction of uterine
arteries, and consequently in the reduced uteroplacental perfusion
and the progression of PE, targeting the contractile response to
ET-1 of uteroplacental arteries could be an effective therapeutic
strategy offering interesting perspectives for the management of
the pathology.
In the present work, we investigated the effect of various drugs
used in the treatment of PE, to inhibit the vasoconstrictive
response of the human uterine artery to ET-1. In particular, we
considered a new option in the management of PE based on the
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16540use of selective ET-1 receptor antagonists (ERAs), and we
evaluated the contribution of DHP-sensitive Ca
2+ channels to
the vasoconstrictive response to ET-1.
Materials and Methods
Tissue collection
The study was approved by the French ministry of research and
higher education (DC-2008-488) and local ethics committee (CPP
Sud Mediterranee-IV) with informed consent in writing from each
patient. Specimens of uterine artery were obtained from thirty
normotensive non-pregnant women (mean age 44 years, range
35–53 years), undergoing hysterectomy for benign gynecological
disorders. None of the selected patients were on hormone therapy
or any other medication and had history of cardiovascular disease.
Immediately after the removal of the uterus, the main branch of
one uterine artery was excised from the parametrium, connective
tissues and adjacent myometrium, placed in physiological saline
buffer (PSS; composition in mM: 140 NaCl, 5 KCl, 1 MgCl2, 0.5
KH2PO4, 0.5 Na2HPO4, 2.5 CaCl2, 10 HEPES, 10 glucose,
pH 7.4) and transported to the laboratory within 30 minutes.
Drugs
The following compounds were used and all purchased from
Sigma-Aldrich: human ET-1, sarafotoxin-S6c (selective ETB
receptor agonist), BQ-123 (selective ETA receptor antagonist),
BQ-788 (selective ETB receptor antagonist), nifedipine and
nicardipine (DHP class of calcium channel blocker), hydralazine,
labetalol (alpha/beta blocker) and alpha-methyldopa (a ´2-adrener-
gic agonist). Compounds were dissolved either in water or in
DMSO and stored as 10 mM or 1 mM stock solutions. Final
molar concentrations in the organ bath are indicated when
necessary in the text. The final concentration of DMSO did not
exceed 0.1% and had no effect on vasoconstriction.
Vascular reactivity
Artery specimens were dissected under a binocular microscope,
isolated from paracervical connective tissues and sixteen segments
of 2–3 mm length were cut. The outer diameter of the vessels was
2 to 3 mm. The endothelium was removed by rubbing and artery
segments were mounted onto thin stainless steel holders and
placed in conventional 5 ml organ bath chambers filled with PSS,
maintained at 37uC and continuously bubbled with O2. Changes
in isometric tension were recorded using an IT1-25 force
transducer and an IOX computerized system (EMKA Technol-
ogies, Paris, France). Experiments were performed as previously
described [17]. Arterial segments were subjected to a 60 min
equilibration period at the predetermined optimal point of its
active length-tension curve established at 2 g by measuring the
contraction to 30 mM potassium chloride (KCl) at different levels
of stretch. The contractile function of each segment and a
maximal contraction was determined with 10 ı `M phenylephrine
(Phe). Preparations were discarded if they failed to contract to Phe
or exhibited spontaneous contractile activity. The removal of
endothelium was confirmed by subsequent application of 1 mM
acetylcholine (Ach); in the absence of endothelium, contractility is
not modified. After a wash (W) and 20–30 minutes period of
stabilization, arterial ring responses to endothelin (ET-1) were
studied. For experiments performed in the presence of antagonists
and vasodilators, preparations were subjected to a 20 min
incubation period with the agent before the addition of ET-1.
Dose-response curves were generated by cumulative increases in
the concentration of ET-1 (range 0.1 nM to 0.5 mM) and
normalized to the contraction induced by Phe (10 mM) in the
same preparation. Relaxing effects of antagonists and antihyper-
tensive drugs were evaluated in arteries contracted with ET-1
(0.1 mM). When the contraction was established, the agent was
added and the tension was then compared to the response to ET-
1. For each compound, the concentrations used corresponded to
doses maximally active. Hydralazine, alpha-methyldopa and
labetalol were used at 100 mM; BQ-123, BQ-788, sarafotoxin-
S6c, nifedipine and nicardipine at 1 mM. At a pharmacological
level, these concentrations corresponded to that maximally active
for each drug. Specific protocols are detailed when necessary in
the legends.
Data analysis
All data are expressed as means 6 standard error of the mean
(S.E.M.), for n specimen of uterine artery. For each specimen,
protocols were performed in triplicate on different arterial rings.
Data were statistically analyzed using one-way ANOVA followed
by a Dunnett post-test. P-values lower than 0.05 were considered
significant. Analyses were performed using GraphPad PrismH
(Graph-Pad Software Inc., San Diego, USA) and EC50 values were
determined using the same software from data fitted with a non-
linear function.
Results
Contractile response to ET-1
ET-1 caused a potent and long lasting contraction of the human
uterine artery. The contraction developed slowly, was sustained
after reaching its maximal amplitude (Fig. 1), was reversed only
partially by the removal of the agonist and could not be induced
again (not shown). The ET-1 induced vasoconstriction was dose-
dependent, with a threshold at approximately 1 nM (Fig. 1A). The
maximal amplitude of 6.761 g, obtained at 0.5 mM ET-1, was
similar to the maximal effect of phenylephrine (10 mM), which
induced a tension of 5.860.7 g (n=10).
Treatment with selective ERAs (BQ-123 for ETA and BQ-788
for ETB) did not change the baseline tone of uterine arteries but
did modify the effect of ET-1 (Fig. 1A). BQ-123 (1 mM) and BQ-
788 (1 mM) competitively antagonized the contraction induced by
ET-1, whereas the amplitude of the contraction elicited by a
maximally active dose of the vasoconstrictor was not affected. The
dose-response curves of ET-1 were slightly shifted to the right by
both antagonists individually and by a combination of the two.
The EC50 value of ET-1 (24.565.6 nM, n=10) was increased
after pre-treatment with BQ-123 (33.961.8 nM, p=0.03, n=10)
but not with BQ-788 (28.862.2 nM, p=0.48, n=10). The
application of BQ-123 and BQ-788 in combination inhibited the
response to ET-1 more efficiently (EC50=48.961.3 nM,
p=0.0001, n=10) (Fig. 1A, upper panel). The response to
10 nM ET-1 was reduced by 50% by BQ-123, and by 62% by the
two antagonists applied together (Fig. 1A, lower panel). For a
saturating concentration of ET-1 (0.5 mM), the inhibitory effects of
antagonists represent only 5% of control values. The two ERAs
alone or in combination did not modify the amplitude of the
contraction induced by the maximal dose of ET-1 (0.5 mM)
(Fig. 1A). BQ-123 and BQ-788, added either alone or in
combination, did not relax arteries pre-contracted with 0.1 mM
ET-1 (Fig. 1B).
Effect of the ETB receptor agonist sarafotoxin
The selective ETB agonist Sarafotoxin-S6c elicited the vaso-
constriction of human uterine arteries (Fig. 2). The maximal
contractile response was weak, reaching only 8.461.4% (n=10) of
the maximal response to ET-1. This agonistic effect was fully
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unaffected by the ETA receptor antagonist BQ-123 (Fig. 2B).
The contraction induced by sarafotoxin-S6c was unaltered by the
DHP nifedipine (1 mM) but was decreased by the extracellular
application of EGTA (10 mM), a Ca
2+-chelating agent (Fig. 2B).
Antagonism of ET-1 induced contraction
Hydralazine, labetalol and alpha-methyldopa (100 mM) did not
affect the contractile response to ET-1 (Fig. 3A) and did not
reverse the contraction induced by ET-1 (Fig. 3B).
Pretreatment with the Ca
2+-chelating agent EGTA (10 mM)
reduced the amplitude of ET-1-induced uterine artery contraction
(Fig. 3A). The contractile response to 0.1 mM ET-1 was
22.364.9% of control levels without EGTA. Furthermore,
10 mM EGTA reversed the contraction elicited by 0.1 mM ET-
1b y9 0 62.9% (p,0.0001, n=10) (Fig. 3B). After pretreatment
with the Ca
2+ channel antagonists nifedipine (1 mM) or nicardi-
pine (1 mM), the effects of the maximal dose of ET-1 (0.5 mM)
were reduced respectively by 39.964% (p,0.005, n=10) and by
37.665.2% (p,0.005, n=10) (Fig. 3A). The same concentrations
of the DHPs also relaxed arteries pre-contracted with ET-1
(0.1 mM), reversing the contraction by 70.565.1% in the case of
nifedipine and by 68.366.6% in the case of nicardipine (Fig. 3B).
In addition, both DHPs partially inhibited the effect of ET-1 at all
Figure 1. Contractile response of the human uterine artery to ET-1 and effect of ET receptor antagonists. (A) Upper panel:
Dose-response curvesobtainedby cumulative increases in theconcentration of ET-1 (0.1 nM–0.1 mM) on basal tone (CTL, ), after pre-incubation for 10
minutes with either an ETA receptor antagonist (BQ-123, 1 mM,N)o ra nE T B receptor antagonist (BQ-788, 1 mM, ), or a mixture of both antagonists (BQ-
123+788, 1 mM,&). Lower panel: Average contraction of uterine artery induced by 10 nM ET-1 with or without a 10 minutes pre-incubation period with
either BQ-123, BQ-788 or BQ123+788 each at 1 mM concentration. Data are expressed as a percentage of the contraction induced by Phe (10 mM). (B)
EffectsofETreceptorantagonistswhenarteries were contractedwithET-1 (0.1 mM).Whenmaximal contractionwas established, ETreceptor antagonists
were added at the same concentrations used in panel A as illustrated on typical recordings of variations of isometric tension (upper panels). Bar graph
represents the average tension after the addition of the drugs, expressed as a percentage of the contraction induced by ET-1 (lower panel). In all
experiments, values indicate the means 6 S.E.M. of 10 different arteries with experiments performed in triplicate.
doi:10.1371/journal.pone.0016540.g001
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shifted to the right: the EC50 increased from 24.565.6 nM in
controls to 38.262.5 nM (p=0.003, n=10) with nifedipine and to
27.964.8 nM (p=0.021, n=10) with nicardipine. At all ET-1
concentrations, the amplitude of the full contractile response was
reduced on average by 50% with nifedipine and with nicardipine.
No difference was observed in terms of efficacy between nifedipine
and nicardipine.
Discussion
ET-1 induced a strong and sustained contraction of the human
uterine artery, which was mediated by both ETA and ETB
receptors. ERAs prevented the contractile response to low ET-1
concentration, but failed either to reduce contraction when ET-1
levels were high or to relax uterine arteries pre-contracted with
ET-1, even when they were combined. Classical antihypertensive
treatments used in PE did not either reverse or prevent ET-1
induced contraction in human uterine artery except for DHPs,
consistently with the involvement of voltage-gated Ca
2+ channels
in the development and, predominantly, in the maintenance of this
response. These results provide an experimental basis to interpret
the failure of PE treatments and to propose a rationale, based on
the use of DHPs, for a potential approach in the management of
the pathology.
Since experiments were performed in endothelium denuded
uterine arteries, our results are consistent with the presence of ET-
1 receptors at the VSMC level. The EC50 value of ET-1 effect
(24.565.6 nM) is in line with previous findings in these and other
vessels [18,19]. The weak agonistic effect of sarafotoxin-S6C and
Figure 2. Effect of sarafotoxin S6c on uterine artery contraction. The effect of sarafotoxin S6c (1 mM) was analyzed with or without a
10-minute pre-incubation period with either 1 mM BQ-123, BQ-788, nifedipine or 10 mM EGTA, and compared to the contraction induced by ET-1
alone (0.1 mM). (A) Representative recordings of isometric tension changes illustrating the effect of sarafotoxin S6c in presence (right panel) or in
absence (left panel) of BQ-123 (other drugs not shown). (B) Average contraction obtained with sarafotoxin S6c under basal conditions (CTL) or in the
presence of BQ-123, BQ-788, EGTA or nifedipine. Data, expressed as a percentage of the contraction induced by ET-1 (0.1 mM) in the same
experiment, indicate the means 6 S.E.M. of 10 different arteries, with experiments performed in triplicate. *** p,0.0001.
doi:10.1371/journal.pone.0016540.g002
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contributes to this regulation even if the vasopressor response to
ET-1 seems to be mainly mediated by ETAR. Synergistic
inhibition by a combination of ERAs, already described for other
blood vessels [20,21], supports the idea that ETAR and ETBR are
simultaneously involved in ET-1-induced contraction of uterine
artery.
Signal transduction pathways for ET-1 related to receptor
subtypes distribution vary between vascular beds and species [22].
In the human uterine artery, the ET-1-induced contraction
depended predominantly (.70%) on Ca
2+ entry, as shown by
experiments in Ca
2+-free conditions with EGTA. Several types of
Ca
2+ channels could be involved in this regulation, especially the
L-type Ca
2+ channels. Nifedipine and nicardipine, the Ca
2+
channel antagonists of choice in PE, blocked half of the ET-1
response at micromolar concentration, supporting the idea that
DHP-sensitive L-type Ca
2+ channels are involved specifically. The
partial inhibition by DHPs together with the effect of EGTA
suggest that ET-1 also activates DHP-insensitive Ca
2+ influx,
which might be through voltage-insensitive receptor-operated
channels (ROCs) or non-selective cation channels (NSCC) [23].
Studies performed on myometrial [24] and on uteroplacental
arteries [25] showed a more pronounced relaxation of ET-1
induced contraction with DHPs, but the high doses used (up to
100 mM) are not consistent with a specific and selective action on
L-type Ca
2+channels [26].
We observed that hydralazine, labetalol and alpha-methyldopa,
antihypertensive drugs used in the treatment of PE, did not modify
either the contraction induced by ET-1 or the response of artery to
the vasoconstrictor. This suggests that, even if they reduce the
systemic hypertension in vivo, these drugs are inefficient to
antagonize the ET-1 induced vasospasm of uterine artery.
Consistently, hydralazine, labetalol and alpha-methyldopa do
not change uteroplacental blood flow in hypertensive pregnant
women [27–29].
Our data also suggest that targeting ET-1 receptors is not a
good option. ETAR and ETBR antagonists prevented ET-1-
induced contraction only partially even with a maximally active
Figure 3. Antagonism of the contraction induced by ET-1. Upper panels represent typical recordings of isometric tension for each condition.
Lower panels are bar graph representations of the respective data. (A) A 10-minute pre-incubation was carried out before contraction was elicited by
ET-1 (0.1 mM), with either EGTA (10 mM), nifedipine or nicardipine (1 mM), or hydralazine, labetalol or alpha-methyldopa (100 mM). Data are expressed
as a percentage of the contraction induced by Phe and represent the maximal tension reached with ET-1 in the presence of the drugs. (B) The artery
was contracted with ET-1 (0.1 mM); derivatives were added when the steady state was established. Data represent the residual tension after the
addition of drugs and are expressed as a percentage of the maximal contraction induced by ET-1. Values indicate the means 6 S.E.M. of 10 different
arteries, with experiments performed in triplicate. *p,0.01, ***p,0.0001.
doi:10.1371/journal.pone.0016540.g003
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concentration is maximal, the inhibition of its effect is barely
significant, in accordance with the action of reversible competitive
antagonists. Moreover, antagonists, applied individually or in
combination, were unable to relax ET-1-precontracted arteries,
which could be explained by the rapid internalization of ET-1/
ETR complexes making the ET-1 binding site no longer accessible
to the ERAs [30]. Our data on uterine artery are in line with
studies performed on myometrial resistance arteries also showing a
partial inhibition of ET-1 induced contraction though contraction
is more pronounced in preeclamptic specimen [31]. Besides the
fact that they are considered teratogenic [32] and contraindicated
in pregnancy [33], ERAs are not expected to do better than Ca
2+
antagonists.
The first aim in the treatment of PE is to control severe acute
hypertension. Treatment is usually administered when mild to
moderate hypertension is detected during pregnancy, in order to
delay or halt the evolution toward severe hypertension, but none
achieves this goal. ET-1 induced vasoconstriction of uterine artery
is supposed to be one contributing factor leading to blood pressure
elevation in PE. We show here that, among treatments used in PE,
only DHPs reverse the contraction of the uterine artery induced by
ET-1 although it does so partially. While these derivatives are
commonly used [34], they do not prevent the progression of the
pathology [7] and although the prolongation of pregnancy is
better with DHPs, as compared to hydralazine and labetalol, the
occurrence of delivery is still premature [35]. One reason could be
that, by the time systemic hypertension occurs, ET-1 concentra-
tions have reached maximal saturating levels in the placenta [36]
not reflected by the slight elevation in plasma levels [37]. Chronic
placental hypoxia/ischemia enhances local ET-1 expression
[38,39], these increases are likely to promote the vasospastic
activity of uterine arteries and thus maintain a vicious cycle of
hypoxia/ischemia and ET-1 production. In this situation, no
improvement is expected in placental perfusion as no relaxation of
ET-1 induced vasoconstriction occurs. Consistent with the effects
of antihypertensive drugs on the reactivity of uterine artery, only
acute antihypertensive treatments with DHPs are expected to
Figure 4. Effect of dihydropyridines on the contractile response of the uterine artery to ET-1. ET-1 concentration was cumulatively
increased (0.1 nM–0.1 mM) with or without a 10-minute pre-incubation period with a DHP. (A) Representative recordings of isometric responses.
(B) Dose response curves obtained for ET-1 in the absence ( ) or in the presence of nifedipine (1 mM, ) or nicardipine (1 mM,&). Data, expressed as
a percentage of the contraction induced by Phe in the same experiment, indicate the means 6 S.E.M. of 10 different arteries with experiments
performed in triplicate. **p,0.001, ***p,0.0001.
doi:10.1371/journal.pone.0016540.g004
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relax uterine arteries maximally constricted, and thus may be
ineffective with respect to placental perfusion. Abnormal utero-
placental blood flow is revealed in uterine artery Doppler
ultrasonography by an increased pulsatility index and a bilateral
notching [40,41]. Thus, as soon as Doppler investigation identifies
abnormalities during the first or second trimester of pregnancy, a
therapy based on the use of DHP derivatives might be set up.
DHPs administrated earlier, i.e. when ET-1 concentrations are not
maximal, are expected to stop the vicious cycle (vasoconstriction
vs. ET-1 production).
One limitation of this study is the use of uterine arteries from
non pregnant and non preeclamptic women. For obvious ethical
and practical reasons, it is not possible to have access to these
arteries either in PE or in pregnancy. In PE, vascular resistance is
increased and it is unlikely to be the consequence of altered
responses to vasoconstrictors. Contractile responses of vascular
smooth muscle to vasoactive agonists and sensitivity of contraction
to changes in intracellular [Ca
2+] does not seem to be affected by
the pathology [42,43]. Even if vascular reactivity is altered, the
ET-1 system is constitutively activated in the pathology as shown
by the lack of effect of exogenous ET-1 in preeclamptic patients
and the down regulation of receptor expression due to the high
levels of ET-1 in uteroplacental circulation [44,45]. Our data show
no or only partial effect of drugs on uterine artery when the ET-1
system is activated. Conclusions raised on the basis of pharma-
cological mechanisms involving ET-1 signaling pathway are
relevant in that context. Moreover, our observations are in line
with the limited clinical efficiency of the drugs currently used in
PE. Labetalol, hydralazine and alpha methyldopa, efficient for
systemic hypertension, have only transient lowering effect on
blood pressure and do not prevent the progression to severe
hypertension. DHPs targeting the mechanisms downstream of ET-
1 signaling may offer more appropriate therapeutic options in that
context.
In conclusion, our data provide some mechanistic insights to
explain the partial failure of PE treatment with antihypertensive
drugs. We showed that hydralazine, labetalol and alpha-
methyldopa do not antagonize the vasoconstriction of uterine
artery induced by ET-1 and, so, they are not supposed to stop the
self-sustained process of vasoconstriction and imbalanced produc-
tion of vasoactive mediators. We do not expect them to slow the
progression of the pathology. DHPs were the most interesting
drugs providing that they are prescribed earlier, ideally before the
onset of severe hypertension. Only under these conditions DHP
derivatives can significantly improve placental perfusion, reverse
placental hypoxia and delay the onset of PE.
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